Dr Colin Rae
- Research Technician (Clinical Research Garscube)
telephone:
01413302850
email:
Colin.Rae@glasgow.ac.uk
Wolfson Wohl Cancer Research Centre, Garscube Estate, Switchback Road, Bearsden, Glasgow, G61 1QH
Publications
2023
O’Rourke, C. J. et al. (2023) Molecular portraits of patients with intrahepatic cholangiocarcinoma who diverge as rapid progressors or long survivors on chemotherapy. Gut, (doi: 10.1136/gutjnl-2023-330748) (PMID:37758326) (Early Online Publication)
Vita, F., Olaizola Rebè, I., Amato, F., Rae, C. , Marco, S., Banales, J. M. and Braconi, C. (2023) Heterogeneity of cholangiocarcinoma immune biology. Cells, 12(6), 846. (doi: 10.3390/cells12060846) (PMID:36980187) (PMCID:PMC10047186)
2022
Raggi, C., Taddei, M. L., Rae, C. , Braconi, C. and Marra, F. (2022) Metabolic reprogramming in cholangiocarcinoma. Journal of Hepatology, 77(3), pp. 849-864. (doi: 10.1016/j.jhep.2022.04.038) (PMID:35594992)
Colyn, L. et al. (2022) New molecular mechanisms in cholangiocarcinoma: signals triggering interleukin-6 production in tumor cells and KRAS co-opted epigenetic mediators driving metabolic reprogramming. Journal of Experimental and Clinical Cancer Research, 41, 183. (doi: 10.1186/s13046-022-02386-2) (PMID:35619118) (PMCID:PMC9134609)
Casolino, R., Amato, F., Rae, C. , Puttagunta, S. and Braconi, C. (2022) Receptor tyrosine kinase co-amplification and benefit from HER2 inhibitors in biliary tract cancers. Journal of Hepatology, 76(5), pp. 1227-1229. (doi: 10.1016/j.jhep.2022.01.012) (PMID:35093472)
2021
Carotenuto, P. et al. (2021) Modulation of pancreatic cancer cell sensitivity to FOLFIRINOX through microRNA-mediated regulation of DNA damage. Nature Communications, 12, 6738. (doi: 10.1038/s41467-021-27099-6) (PMID:34795259) (PMCID:PMC8602334)
Nile, D. L., Rae, C. , Walker, D. J. , Canning Waddington, J., Vincent, I. , Burgess, K., Gaze, M. N., Mairs, R. J. and Chalmers, A. J. (2021) Inhibition of glycolysis and mitochondrial respiration promotes radiosensitisation of neuroblastoma and glioma cells. Cancer and Metabolism, 9, 24. (doi: 10.1186/s40170-021-00258-5) (PMID:34011385) (PMCID:PMC8136224)
Rae, C. , Amato, F. and Braconi, C. (2021) Patient-derived organoids as a model for cancer drug discovery. International Journal of Molecular Sciences, 22(7), 3483. (doi: 10.3390/ijms22073483) (PMID:33801782) (PMCID:PMC8038043)
2020
Rae, C. , Fragkoulis, G. I. and Chalmers, A. J. (2020) Cytotoxicity and radiosensitizing activity of the fatty acid synthase inhibitor C75 is enhanced by blocking fatty acid uptake in prostate cancer cells. Advances in Radiation Oncology, 5(5), pp. 944-1005. (doi: 10.1016/j.adro.2020.06.022) (PMID:33083663) (PMCID:PMC7557210)
Amato, F., Rae, C. , Prete, M. G. and Braconi, C. (2020) Cholangiocarcinoma disease modelling through patients derived organoids. Cells, 9(4), 832. (doi: 10.3390/cells9040832) (PMID:32235647) (PMCID:PMC7226733)
2019
Rae, C. and Mairs, R. J. (2019) AMPK activation by AICAR sensitizes prostate cancer cells to radiotherapy. Oncotarget, 10(7), pp. 749-759. (doi: 10.18632/oncotarget.26598) (PMID:30774777) (PMCID:PMC6366825)
2018
Tesson, M., Vasan, R. , Hock, A., Nixon, C., Rae, C. , Gaze, M. and Mairs, R. (2018) An evaluation in vitro of the efficacy of nutlin-3 and topotecan in combination with 177 Lu-DOTATATE for the treatment of neuroblastoma. Oncotarget, 9(49), pp. 29082-29096. (doi: 10.18632/oncotarget.25607) (PMID:30018737) (PMCID:PMC6044389)
Nile, D. L., Rae, C. , Nixon, C., Gaze, M. N. and Mairs, R. J. (2018) The suppression of DNA repair induced by PARP-1 inhibitors rucaparib and olaparib in combination with the radiopharmaceutical 131I-MIBG in noradrenaline transporter-expressing xenograft tumors. Cancer Therapy and Oncology International Journal, 10(3), 555788. (doi: 10.19080/CTOIJ.2018.10.555788)
Rae, C. , Sey, C.H.C. and Mairs, R.J. (2018) Radiosensitization of prostate cancer cells by 2-deoxyglucose. Madridge Journal of Oncogenesis, 2(1), pp. 30-34.
2017
Tesson, M., Rae, C. , Nile, D. L., Mairs, R. and Gaze, M. N. (2017) Targeted radiotherapy of neuroblastoma: future directions. Integrative Cancer Science and Therapeutics, 4(6), pp. 1-2. (doi: 10.15761/ICST.1000260)
Rae, C. , Babich, J. W. and Mairs, R. J. (2017) Differential in radiosensitizing potency of enantiomers of the fatty acid synthase inhibitor C75. Chirality, 29(1), pp. 10-13. (doi: 10.1002/chir.22668) (PMID:27901292) (PMCID:PMC5248592)
Rae, C. and Mairs, R. J. (2017) Evaluation of the radiosensitizing potency of chemotherapeutic agents in prostate cancer cells. International Journal of Radiation Biology, 93(2), pp. 194-203. (doi: 10.1080/09553002.2017.1231946) (PMID:27600766)
2016
Nile, D. L., Rae, C. , Hyndman, I. J., Gaze, M. N. and Mairs, R. J. (2016) An evaluation in vitro of PARP-1 inhibitors, rucaparib and olaparib, as radiosensitisers for the treatment of neuroblastoma. BMC Cancer, 16, 621. (doi: 10.1186/s12885-016-2656-8) (PMID:27515310) (PMCID:PMC4982014)
Tesson, M., Rae, C. , Nixon, C., Babich, J. W. and Mairs, R. J. (2016) Preliminary evaluation of prostate-targeted radiotherapy using 131I-MIP-1095 in combination with radiosensitising chemotherapeutic drugs. Journal of Pharmacy and Pharmacology, 68(7), pp. 912-921. (doi: 10.1111/jphp.12558) (PMID:27139157) (PMCID:PMC5298040)
2015
Rae, C. , Haberkorn, U., Babich, J. W. and Mairs, R. J. (2015) Inhibition of fatty acid synthase sensitizes prostate cancer cells to radiotherapy. Radiation Research, 184(5), pp. 482-493. (doi: 10.1667/RR14173.1)
2014
Hutchison, S., Rae, C. , Tesson, M., Babich, J., Boyd, M. and Mairs, R. (2014) Evaluation of melanin-targeted radiotherapy in combination with radiosensitizing drugs for the treatment of melanoma. Cancer and Oncology Research, 2(4), pp. 58-67. (doi: 10.13189/cor.2014.020403)
2013
Rae, C. , Tesson, M., Babich, J.W., Boyd, M., Sorensen, A. and Mairs, R. (2013) The role of copper in disulfiram-induced toxicity and radiosensitization of cancer cells. Journal of Nuclear Medicine, 54(6), pp. 953-960. (doi: 10.2967/jnumed.112.113324)
Rae, C. , Tesson, M., Babich, J.W., Boyd, M. and Mairs, R.J. (2013) Radiosensitization of noradrenaline transporter-expressing tumour cells by proteasome inhibitors and the role of reactive oxygen species. EJNMMI Research, 3(73), (doi: 10.1186/2191-219X-3-73)
2009
Sureshbabu, A. et al. (2009) IGFBP-5 induces epithelial and fibroblast responses consistent with the fibrotic response. Biochemical Society Transactions, 37(4), pp. 882-885. (doi: 10.1042/BST0370882)
Robertson, S.A., Rae, C. and Graham, A. (2009) Resistin: TWEAKing angiogenesis. Atherosclerosis, 203(1), pp. 34-37. (doi: 10.1016/j.atherosclerosis.2008.05.040)
Robertson, S.A., Rae, C. and Graham, A. (2009) Induction of angiogenesis by murine resistin: putative role of PI3-kinase and NO-dependent pathways. Regulatory Peptides, 152(1-3), pp. 41-47. (doi: 10.1016/j.regpep.2008.07.008)
2008
Rae, C. and Graham, A. (2008) Fatty acid synthase inhibitor, C75, blocks resistin-induced increases in lipid accumulation by human macrophages. Diabetes, Obesity and Metabolism, 10(12), pp. 1271-1274. (doi: 10.1111/j.1463-1326.2008.00962.x)
2007
Rae, C. , Robertson, S. A., Taylor, J. M.W. and Graham, A. (2007) Resistin induces lipolysis and re-esterification of triacylglycerol stores, and increases cholesteryl ester deposition, in human macrophage. FEBS Letters, 581(25), pp. 4877-4883. (doi: 10.1016/j.febslet.2007.09.014)
Rae, C. , Langa, S., Tucker, S.J. and MacEwan, D.J. (2007) Elevated NF-kappaB responses and FLIP levels in leukemic but not normal lymphocytes: reduction by salicylate allows TNF-induced apoptosis. Proceedings of the National Academy of Sciences of the United States of America, 104(31), pp. 12790-12795. (doi: 10.1073/pnas.0701437104)
2006
Rae, C. , Cherry, J.I., Land, F.M. and Land, S.C. (2006) Endotoxin-induced nitric oxide production rescues airway growth and maturation in atrophic fetal rat lung explants. Biochemical and Biophysical Research Communications, 349(1), pp. 416-425. (doi: 10.1016/j.bbrc.2006.08.067)
Rae, C. and Graham, A. (2006) Human resistin promotes macrophage lipid accumulation. Diabetologia, 49(5), pp. 1112-1114. (doi: 10.1007/s00125-006-0187-6)
2005
Land, S.C. and Rae, C. (2005) iNOS initiates and sustains metabolic arrest in hypoxic lung adenocarcinoma cells: mechanism of cell survival in solid tumor core. American Journal of Physiology, 289(4), C918-C933. (doi: 10.1152/ajpcell.00476.2004)
2004
Rae, C. and MacEwan, D.J. (2004) Granulocyte macrophage-colony stimulating factor and interleukin-3 increase expression of type II tumour necrosis factor receptor, increasing susceptibility to tumour necrosis factor-induced apoptosis. Control of leukaemia cell life/death switching. Cell Death and Differentiation, 11(S2), S162-S171. (doi: 10.1038/sj.cdd.4401494)
Tucker, S.J., Rae, C. , Littlejohn, A.F., Paul, A. and MacEwan, D.J. (2004) Switching leukemia cell phenotype between life and death. Proceedings of the National Academy of Sciences of the United States of America, 101(35), pp. 12940-12945. (doi: 10.1073/pnas.0400949101)
Articles
O’Rourke, C. J. et al. (2023) Molecular portraits of patients with intrahepatic cholangiocarcinoma who diverge as rapid progressors or long survivors on chemotherapy. Gut, (doi: 10.1136/gutjnl-2023-330748) (PMID:37758326) (Early Online Publication)
Vita, F., Olaizola Rebè, I., Amato, F., Rae, C. , Marco, S., Banales, J. M. and Braconi, C. (2023) Heterogeneity of cholangiocarcinoma immune biology. Cells, 12(6), 846. (doi: 10.3390/cells12060846) (PMID:36980187) (PMCID:PMC10047186)
Raggi, C., Taddei, M. L., Rae, C. , Braconi, C. and Marra, F. (2022) Metabolic reprogramming in cholangiocarcinoma. Journal of Hepatology, 77(3), pp. 849-864. (doi: 10.1016/j.jhep.2022.04.038) (PMID:35594992)
Colyn, L. et al. (2022) New molecular mechanisms in cholangiocarcinoma: signals triggering interleukin-6 production in tumor cells and KRAS co-opted epigenetic mediators driving metabolic reprogramming. Journal of Experimental and Clinical Cancer Research, 41, 183. (doi: 10.1186/s13046-022-02386-2) (PMID:35619118) (PMCID:PMC9134609)
Casolino, R., Amato, F., Rae, C. , Puttagunta, S. and Braconi, C. (2022) Receptor tyrosine kinase co-amplification and benefit from HER2 inhibitors in biliary tract cancers. Journal of Hepatology, 76(5), pp. 1227-1229. (doi: 10.1016/j.jhep.2022.01.012) (PMID:35093472)
Carotenuto, P. et al. (2021) Modulation of pancreatic cancer cell sensitivity to FOLFIRINOX through microRNA-mediated regulation of DNA damage. Nature Communications, 12, 6738. (doi: 10.1038/s41467-021-27099-6) (PMID:34795259) (PMCID:PMC8602334)
Nile, D. L., Rae, C. , Walker, D. J. , Canning Waddington, J., Vincent, I. , Burgess, K., Gaze, M. N., Mairs, R. J. and Chalmers, A. J. (2021) Inhibition of glycolysis and mitochondrial respiration promotes radiosensitisation of neuroblastoma and glioma cells. Cancer and Metabolism, 9, 24. (doi: 10.1186/s40170-021-00258-5) (PMID:34011385) (PMCID:PMC8136224)
Rae, C. , Amato, F. and Braconi, C. (2021) Patient-derived organoids as a model for cancer drug discovery. International Journal of Molecular Sciences, 22(7), 3483. (doi: 10.3390/ijms22073483) (PMID:33801782) (PMCID:PMC8038043)
Rae, C. , Fragkoulis, G. I. and Chalmers, A. J. (2020) Cytotoxicity and radiosensitizing activity of the fatty acid synthase inhibitor C75 is enhanced by blocking fatty acid uptake in prostate cancer cells. Advances in Radiation Oncology, 5(5), pp. 944-1005. (doi: 10.1016/j.adro.2020.06.022) (PMID:33083663) (PMCID:PMC7557210)
Amato, F., Rae, C. , Prete, M. G. and Braconi, C. (2020) Cholangiocarcinoma disease modelling through patients derived organoids. Cells, 9(4), 832. (doi: 10.3390/cells9040832) (PMID:32235647) (PMCID:PMC7226733)
Rae, C. and Mairs, R. J. (2019) AMPK activation by AICAR sensitizes prostate cancer cells to radiotherapy. Oncotarget, 10(7), pp. 749-759. (doi: 10.18632/oncotarget.26598) (PMID:30774777) (PMCID:PMC6366825)
Tesson, M., Vasan, R. , Hock, A., Nixon, C., Rae, C. , Gaze, M. and Mairs, R. (2018) An evaluation in vitro of the efficacy of nutlin-3 and topotecan in combination with 177 Lu-DOTATATE for the treatment of neuroblastoma. Oncotarget, 9(49), pp. 29082-29096. (doi: 10.18632/oncotarget.25607) (PMID:30018737) (PMCID:PMC6044389)
Nile, D. L., Rae, C. , Nixon, C., Gaze, M. N. and Mairs, R. J. (2018) The suppression of DNA repair induced by PARP-1 inhibitors rucaparib and olaparib in combination with the radiopharmaceutical 131I-MIBG in noradrenaline transporter-expressing xenograft tumors. Cancer Therapy and Oncology International Journal, 10(3), 555788. (doi: 10.19080/CTOIJ.2018.10.555788)
Rae, C. , Sey, C.H.C. and Mairs, R.J. (2018) Radiosensitization of prostate cancer cells by 2-deoxyglucose. Madridge Journal of Oncogenesis, 2(1), pp. 30-34.
Tesson, M., Rae, C. , Nile, D. L., Mairs, R. and Gaze, M. N. (2017) Targeted radiotherapy of neuroblastoma: future directions. Integrative Cancer Science and Therapeutics, 4(6), pp. 1-2. (doi: 10.15761/ICST.1000260)
Rae, C. , Babich, J. W. and Mairs, R. J. (2017) Differential in radiosensitizing potency of enantiomers of the fatty acid synthase inhibitor C75. Chirality, 29(1), pp. 10-13. (doi: 10.1002/chir.22668) (PMID:27901292) (PMCID:PMC5248592)
Rae, C. and Mairs, R. J. (2017) Evaluation of the radiosensitizing potency of chemotherapeutic agents in prostate cancer cells. International Journal of Radiation Biology, 93(2), pp. 194-203. (doi: 10.1080/09553002.2017.1231946) (PMID:27600766)
Nile, D. L., Rae, C. , Hyndman, I. J., Gaze, M. N. and Mairs, R. J. (2016) An evaluation in vitro of PARP-1 inhibitors, rucaparib and olaparib, as radiosensitisers for the treatment of neuroblastoma. BMC Cancer, 16, 621. (doi: 10.1186/s12885-016-2656-8) (PMID:27515310) (PMCID:PMC4982014)
Tesson, M., Rae, C. , Nixon, C., Babich, J. W. and Mairs, R. J. (2016) Preliminary evaluation of prostate-targeted radiotherapy using 131I-MIP-1095 in combination with radiosensitising chemotherapeutic drugs. Journal of Pharmacy and Pharmacology, 68(7), pp. 912-921. (doi: 10.1111/jphp.12558) (PMID:27139157) (PMCID:PMC5298040)
Rae, C. , Haberkorn, U., Babich, J. W. and Mairs, R. J. (2015) Inhibition of fatty acid synthase sensitizes prostate cancer cells to radiotherapy. Radiation Research, 184(5), pp. 482-493. (doi: 10.1667/RR14173.1)
Hutchison, S., Rae, C. , Tesson, M., Babich, J., Boyd, M. and Mairs, R. (2014) Evaluation of melanin-targeted radiotherapy in combination with radiosensitizing drugs for the treatment of melanoma. Cancer and Oncology Research, 2(4), pp. 58-67. (doi: 10.13189/cor.2014.020403)
Rae, C. , Tesson, M., Babich, J.W., Boyd, M., Sorensen, A. and Mairs, R. (2013) The role of copper in disulfiram-induced toxicity and radiosensitization of cancer cells. Journal of Nuclear Medicine, 54(6), pp. 953-960. (doi: 10.2967/jnumed.112.113324)
Rae, C. , Tesson, M., Babich, J.W., Boyd, M. and Mairs, R.J. (2013) Radiosensitization of noradrenaline transporter-expressing tumour cells by proteasome inhibitors and the role of reactive oxygen species. EJNMMI Research, 3(73), (doi: 10.1186/2191-219X-3-73)
Sureshbabu, A. et al. (2009) IGFBP-5 induces epithelial and fibroblast responses consistent with the fibrotic response. Biochemical Society Transactions, 37(4), pp. 882-885. (doi: 10.1042/BST0370882)
Robertson, S.A., Rae, C. and Graham, A. (2009) Resistin: TWEAKing angiogenesis. Atherosclerosis, 203(1), pp. 34-37. (doi: 10.1016/j.atherosclerosis.2008.05.040)
Robertson, S.A., Rae, C. and Graham, A. (2009) Induction of angiogenesis by murine resistin: putative role of PI3-kinase and NO-dependent pathways. Regulatory Peptides, 152(1-3), pp. 41-47. (doi: 10.1016/j.regpep.2008.07.008)
Rae, C. and Graham, A. (2008) Fatty acid synthase inhibitor, C75, blocks resistin-induced increases in lipid accumulation by human macrophages. Diabetes, Obesity and Metabolism, 10(12), pp. 1271-1274. (doi: 10.1111/j.1463-1326.2008.00962.x)
Rae, C. , Robertson, S. A., Taylor, J. M.W. and Graham, A. (2007) Resistin induces lipolysis and re-esterification of triacylglycerol stores, and increases cholesteryl ester deposition, in human macrophage. FEBS Letters, 581(25), pp. 4877-4883. (doi: 10.1016/j.febslet.2007.09.014)
Rae, C. , Langa, S., Tucker, S.J. and MacEwan, D.J. (2007) Elevated NF-kappaB responses and FLIP levels in leukemic but not normal lymphocytes: reduction by salicylate allows TNF-induced apoptosis. Proceedings of the National Academy of Sciences of the United States of America, 104(31), pp. 12790-12795. (doi: 10.1073/pnas.0701437104)
Rae, C. , Cherry, J.I., Land, F.M. and Land, S.C. (2006) Endotoxin-induced nitric oxide production rescues airway growth and maturation in atrophic fetal rat lung explants. Biochemical and Biophysical Research Communications, 349(1), pp. 416-425. (doi: 10.1016/j.bbrc.2006.08.067)
Rae, C. and Graham, A. (2006) Human resistin promotes macrophage lipid accumulation. Diabetologia, 49(5), pp. 1112-1114. (doi: 10.1007/s00125-006-0187-6)
Land, S.C. and Rae, C. (2005) iNOS initiates and sustains metabolic arrest in hypoxic lung adenocarcinoma cells: mechanism of cell survival in solid tumor core. American Journal of Physiology, 289(4), C918-C933. (doi: 10.1152/ajpcell.00476.2004)
Rae, C. and MacEwan, D.J. (2004) Granulocyte macrophage-colony stimulating factor and interleukin-3 increase expression of type II tumour necrosis factor receptor, increasing susceptibility to tumour necrosis factor-induced apoptosis. Control of leukaemia cell life/death switching. Cell Death and Differentiation, 11(S2), S162-S171. (doi: 10.1038/sj.cdd.4401494)
Tucker, S.J., Rae, C. , Littlejohn, A.F., Paul, A. and MacEwan, D.J. (2004) Switching leukemia cell phenotype between life and death. Proceedings of the National Academy of Sciences of the United States of America, 101(35), pp. 12940-12945. (doi: 10.1073/pnas.0400949101)